Low-dose methotrexate as treatment of myeloproliferative neoplasms: Proof of principle of clinical activity

Am J Hematol. 2016 Aug;91(8):E329-30. doi: 10.1002/ajh.24406. Epub 2016 Jun 3.

Authors

Francesca Palandri¹, Claudia Labate², Elena Sabattini³, Lucia Catani¹, Bruno Martino²

Affiliations

¹ Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "L. and a. Seràgnoli," University of Bologna, Bologna, Italy.
² Division of Hematology, Azienda Ospedaliera "Bianchi Melacrino Morelli, "Reggio Calabria, Italy.
³ Hematopathology Unit, Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.

PMID: 27145026
DOI: 10.1002/ajh.24406

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antimetabolites, Antineoplastic / administration & dosage*
Female
Humans
Male
Methotrexate / administration & dosage*
Middle Aged
Myeloproliferative Disorders / blood
Myeloproliferative Disorders / diagnosis
Myeloproliferative Disorders / drug therapy*
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Methotrexate